International
A twice-a-year injection could help women avoid HIV infection, according to a trial involving adolescent girls and young women in South Africa and Uganda. The study compared daily pre-exposure prophylaxis (PrEP) tablets with a twice-yearly injection of a drug called lenacapavir. They found that none of the women and girls who received the long-acting injections acquired HIV. They also found that HIV incidence was lower with the injections than the usual rate of HIV in the community, and also lower than with the daily PrEP tablets.
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Sign In
